SNMMI continues advocacy on utility of amyloid imaging

03/27/2013 | MolecularImaging.net

SNMMI and the Alzheimer's Association will meet with CMS officials next month to discuss appropriate use criteria concerning the use of amyloid imaging in evaluating and diagnosing Alzheimer's disease. SNMMI President Frederic H. Fahey said SNMMI "will recommend coverage for the three indications specified by the AUC." Amyloid imaging is not currently reimbursed.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Food Lawyer
Cargill
Wayzata, MN
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ